Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zifivax Booster in Children and Adolescents
NCT05895110Completed
- Sponsor
- Zhifei Biological
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of ZF2001 in coronavirus disease 2019 (COVID-19), sponsored by Zhifei Biological. Primary endpoint: SARS-COV-2 neutralizing antibody at 6 months. Started Apr 2022; status: completed.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05895110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895110.